Mavenir Introduces Mobile Business Fabric™ to Transform Business Communications for Deskless Mobile Workers
8.10.2019 15:00:00 EEST | Business Wire | Press release
Mavenir, the industry’s only end-to-end, cloud-native Network Software Provider, today announced its Mobile Business Fabric™, a dynamic and fluid business communications framework designed to meet the evolving digital needs of businesses as mobility becomes a primary driver and customers demand change.
Mavenir’s Mobile Business Fabric™ consists of a portfolio of integrated business solutions with a focus on enabling deskless, mobile workers for businesses of all sizes—from SMBs to large enterprises. This portfolio integrates mobile voice, mobile video, rich communication services (RCS) and SMS messaging, voicemail, interactive voice response (IVR), chatbots, SpamShield™ fraud management and monetization enablers into secure, carrier-grade cloud offerings.
These are combined with digital enablement capabilities for provisioning, onboarding, and invoicing businesses via an intuitive, omnichannel interface. This embedded functionality avoids long, complex and costly integrations with the existing legacy business support systems (BSS) of the service provider or channel partner, accelerating time-to-market and time-to-revenue.
Mavenir’s Mobile Business Fabric solutions are currently deployed and under deployment in several Tier 1 MNOs in the US, UK, Spain, Germany, India and Japan.
“Mavenir’s vision is to transform mobile network economics and accelerate the business transformation for mobile operators and channel partners,” said Guillaume Le Mener, SVP and GM, Mobile Enterprise Solutions, Mavenir. “Mobile Business Fabric is a cohesive portfolio that provides true mobile-native experiences and addresses the deskless mobile user base to generate additional revenue streams, protect their existing customer base and reduce customer churn.”
Supporting Information:
- Today, 80% of the global workforce are mobile “deskless” first line workers and the top 8 deskless industries—agriculture, education, healthcare, retail, hospitality, manufacturing, transportation and construction—employ 2.7 billion employeesi.
- Deskless mobile workers require simplified workflows leveraging their powerful mobile devices on the go.
- Today, the majority of solutions in the market have been designed for office workers and then adapted to include some limited mobility capabilities. This can lead to user frustration, particularly for emerging mobile small and medium businesses (SMBs), which have been underserved.
Mavenir’s Mobile Business Fabric flips the paradigm over with a mobile-native portfolio that doesn’t require IT administrators, hardware investments, or complex device management, while providing seamless onboarding to help accelerate time to revenue.
“As an innovative and agile Software as a Service (SaaS) solution, Mavenir’s Mobile Business Fabric portfolio enables our global partners to target the Enterprise market, as well as the underserved SMB segment,” said Marek Wasilewski, SVP, Global Enterprise Channel. “Our disruptive solutions designed for the deskless mobile workers—who typically have an I want to do it myself and I want it now mentality—simplify onboarding, remove management complexity, and, ultimately, are focused on adding positive business outcomes."
The Mobile Business Fabric portfolio comes to market with the following solutions:
- Mobile Business Messaging — RCS Business Messaging as a service that enables MNOs to address the brands’ need to communicate with customers on the mobile messaging channel—including marketing campaigns (A2P) and chatbots (P2A)—leveraging Mavenir’s RBM Partner Ecosystem to accelerate time-to-revenue.
- Mobile Business Contact — Helping businesses of all sizes to minimize the number of missed business opportunities with a white label omni-channel contact center as a service (CCaaS) designed for quick and easy access. It enables seamless omni-channel (phone, email, chat, text-message, social) interactions with customers; with fast deployment using pre-built templates and API integrations with popular tools and AI platforms.
- Mobile Business Communications and Collaboration — unified communications and collaboration as a service (UCaaS) built on mobile call control elements, that leverages mobile network quality of service (QoS) enforcement as well as RCS messaging to allow businesses to text with both internal and external users, breaking the traditional restrictions of proprietary instant messaging implementations.
The Mobile Business Fabric solutions announced are available today as a service hosted from the Mavenir cloud or deployed in the service provider’s network. Mavenir is already adapting more products and solutions into the Fabric, expected in early 2020.
To learn more, visit Mavenir's Mobile Business Fabric page.
NOTE: Mavenir will be showcasing Mobile Business Fabric with live demos at Mobile World Congress 2019 Los Angeles. To request a meeting, visit https://mavenir.com/buzz/events/mwc-la-2019
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native network software provider. Focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and Virtualized RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2019 Mavenir Systems, Inc. All Rights Reserved.
i Emergence: Rise of the Deskless Workforce, 2018
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005042/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Loren Guertin
MatterNow
mavenir@matternow.com
Kevin Taylor
GlobalResultsPR
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
